Shots:
- Trial assessed Lilly’s retatrutide (4, 9 & 12mg) with dose escalation vs PBO in adults with obesity/overweight & ≥1 weight-related comorbidity & without diabetes, meeting 1EP of 19% (4mg), 25.9% (9mg) & 28.3% (12mg) weight loss at 80wks.
- In 2EPs, retatrutide reduced waist circumference by 16.3cm (4mg), 21.8cm (9mg), & 24.1cm (12mg) vs 3.6cm. Rates of ≥25% weight loss were 27.8%, 52.9% & 62.5% vs 2.2%; ≥30% weight loss were 15.3%, 37.9%, & 45.3% vs 0.5%; and ≥35% weight loss were 5.9%, 20.8%, & 27.2%, vs 0.3%.
- At 104wks., mean weight reductions reached 27.9%, 29.5% & 30.3%, while PBO pts switched to retatrutide achieved a 19.2% reduction. For the treatment-regimen estimand, weight loss at 80wks. was 17.6%, 23.7%, & 25% vs 3.9%, while at 104wks., it was 25.7%, 28.7%, & 29.9% across the respective dose-to-MTD groups, while PBO-to-MTD pts achieved an 18.9% reduction. CV risk factors were also improved
Ref: PRnewswire | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports Positive P-III (ACHIEVE-4) Data of Foundayo in Type 2 Diabetes and Obesity or Overweight
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
